Rachel Wittenberg

Ms. Rachel Wittenberg

University of Oxford, Oxford, UK
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2020 in npj Vaccines
Verified
Journal Article
Open access
PDF file
Paulo J. G. BettencourtPaulo J. G. Bettencourt
Paulo J. G. Bettencourt
JMJulius Müller
Julius Müller
ANAnnalisa Nicastri
Annalisa Nicastri
DCDaire cantillon
Daire cantillon
MMMeera Madhavan
Meera Madhavan
HMHelen McShane
Helen McShane
Mycobacterium tuberculosis(M.tb) is responsible for more deaths globally than any other pathogen. The only available vaccine, bacillus Calmette-Guérin (BCG), has variable efficacy throughout the world. A more effective vaccine is urgently needed. The immune response against tuberculosis relies, at least in part, on CD4+T cells. Protective vaccines require the induction of antigen-specific CD4+T cells via mycobacterial peptides presented by MHC class-II in infected macrophages. In order to identify mycobacterial antigens bound to MHC, we have immunoprecipitated MHC class-I and class-II complexes from THP-1 macrophages infected with BCG, purified MHC class-I and MHC class-II peptides and analysed them by liquid chromatography tandem mass spectrometry. We have successfully identified 94 mycobacterial peptides presented by MHC-II and 43 presented by MHC-I, from 76 and 41 antigens, respectively. These antigens were found to be highly expressed in infected macrophages. Gene ontology analysis suggests most of these antigens are associated with membranes and involved in lipid biosynthesis and transport. The sequences of selected peptides were confirmed by spectral match validation and immunogenicity evaluated by IFN-gamma ELISpot against peripheral blood mononuclear cell from volunteers vaccinated with BCG,M.tblatently infected subjects or patients with tuberculosis disease. Three antigens were expressed in viral vectors, and evaluated as vaccine candidates alone or in combination in a murine aerosolM.tbchallenge model. When delivered in combination, the three candidate vaccines conferred significant protection in the lungs and spleen compared with BCG alone, demonstrating proof-of-concept for this unbiased approach to identifying new candidate antigens.

10 January 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
RTRachel Tanner
Rachel Tanner
ISIman Satti
Iman Satti
SHStephanie A. Harris
Stephanie A. Harris
MOMatthew K. O'SHea
Matthew K. O'SHea
DCDeniz Cizmeci
Deniz Cizmeci
HMHelen McShane
Helen McShane
Tuberculosis (TB) remains a leading global cause of morbidity and mortality and an effective new vaccine is urgently needed. A major barrier to the rational development of novel TB vaccines is the lack of a validated immune correlate or biomarker of protection. Mycobacterial Growth Inhibition Assays (MGIAs) provide an unbiased measure of ability to control mycobacterial growth in vitro, and may represent a functional correlate of protection. However, the biological relevance of any potential correlate can only be assessed by determining the association with in vivo protection from either a controlled mycobacterial infection or natural development of TB disease. Our data demonstrate that the direct MGIA using peripheral blood mononuclear cells (PBMC) is measuring a biologically relevant response that correlates with protection from in vivo human BCG infection across two independent cohorts. This is the first report of an MGIA correlating with in vivo protection in the species-of-interest, humans, and furthermore on a per-individual as well as per-group basis. Control of mycobacterial growth in the MGIA is associated with a range of immune parameters measured post-BCG infection in vivo including the IFN-γ ELISpot response, frequency of PPD-specific IFN-γ or TNF-α producing CD4+ T cells and frequency of specific sub-populations of polyfunctional CD4+ T cells. Distinct transcriptomic profiles are associated with good vs. poor mycobacterial control in the MGIA, with good controllers showing enrichment for gene sets associated with antigen processing/presentation and the IL-23 pathway, and poor controllers showing enrichment for hypoxia-related pathways. This study represents an important step toward biologically validating the direct PBMC MGIA for use in TB vaccine development and furthermore demonstrates the utility of this assay in determining relevant immune mechanisms and pathways of protection.

3 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
ISIman Satti
Iman Satti
RWRachel Wittenberg
Rachel Wittenberg
SLShuailin Li
Shuailin Li
SHStephanie A. Harris
Stephanie A. Harris
RTRachel Tanner
Rachel Tanner
HMHelen McShane
Helen McShane
Tuberculosis vaccine development is hindered by the lack of validated immune correlates of protection. Exploring immune correlates of risk of disease and/or infection in prospective samples can inform this field. We investigate whether previously identified immune correlates of risk of TB disease also associate with increased risk of M.tb infection in BCG-vaccinated South African infants, who became infected with M.tb during 2-3 years of follow-up. M.tb infection is defined by conversion to positive reactivity in the QuantiFERON test. We demonstrate that inflammation and immune activation are associated with risk of M.tb infection. Ag85A-specific IgG is elevated in infants that were subsequently infected with M.tb, and this is coupled with upregulated gene expression of immunoglobulin-associated genes and type-I interferon. Plasma levels of IFN- $$\alpha$$ α 2, TNF- $$\alpha$$ α , CXCL10 (IP-10) and complement C2 are also higher in infants that were subsequently infected with M.tb.

4 January 2021 in npj Vaccines
Verified
Journal Article
Open access
PDF file
RTRachel Tanner
Rachel Tanner
AWAndrew White
Andrew White
CBCharelle Boot
Charelle Boot
CSClaudia C. Sombroek
Claudia C. Sombroek
MOMatthew K. O’sHea
Matthew K. O’sHea
HMHelen McShane
Helen McShane
We present a non-human primate mycobacterial growth inhibition assay (MGIA) using in vitro blood or cell co-culture with the aim of refining and expediting early tuberculosis vaccine testing. We have taken steps to optimise the assay using cryopreserved peripheral blood mononuclear cells, transfer it to end-user institutes, and assess technical and biological validity. Increasing cell concentration or mycobacterial input and co-culturing in static 48-well plates compared with rotating tubes improved intra-assay repeatability and sensitivity. Standardisation and harmonisation efforts resulted in high consistency agreements, with repeatability and intermediate precision <10% coefficient of variation (CV) and inter-site reproducibility <20% CV; although some systematic differences were observed. As proof-of-concept, we demonstrated ability to detect a BCG vaccine-induced improvement in growth inhibition in macaque samples, and a correlation between MGIA outcome and measures of protection from in vivo disease development following challenge with either intradermal BCG or aerosol/endobronchial Mycobacterium tuberculosis (M.tb) at a group and individual animal level.

2 July 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
RWRachel Wittenberg
Rachel Wittenberg
KGKimberlee Gauvreau
Kimberlee Gauvreau
CDChris Duggan
Chris Duggan
XDXinwei Du
Xinwei Du
DGDo Giang
Do Giang
Kathy J. JenkinsKathy J. Jenkins
Kathy J. Jenkins
Background: High energy requirements and poor feeding can lead to growth failure in patients with ventricular septal defect (VSD), but effects of preoperative malnutrition on surgical outcomes are poorly understood, especially in low‐resource settings. Methods and Results: We analyzed a cohort of children <5 years of age undergoing VSD closure at 60 global centers participating in the International Quality Improvement Collaborative for Congenital Heart Disease, 2015 to 2020. We calculated adjusted odds ratios (ORs) for in‐hospital death and major infection and adjusted coefficients for duration of intensive care unit stay for 4 measures of malnutrition: severe wasting (weight‐for‐height Z score, <−3), moderate wasting (−3<weight‐for‐height Z score≤−2), underweight (weight‐for‐age Z score, ≤−2), and stunting (height‐for‐age Z score, ≤−2) according to World Health Organization Child Growth Standards. Among 10 966 children undergoing VSD closure in the analyzed cohort, 8136 (74%) were membranous VSDs. Median age was 9.6 months (interquartile range, 3.6–12.0), and 4088 (37.3%) had wasting/severe wasting, 5029 (45.9%) had underweight, and 3515 (32.1%) had stunting. There were 4749 (43.3%) children who met the criteria for ≥2 malnutrition categories. Overall, 84 patients (0.8%) died in‐hospital, and 199 (1.8%) had major infection. Severe wasting (OR, 3.38 [95% CI, 1.55–7.35]; P =0.002), underweight (OR, 6.46 [95% CI, 2.81–14.8]; P <0.001), and stunting (OR, 2.73 [95% CI, 1.40–5.34]; P =0.003) were independent predictors of mortality. Similar results were observed for infection and duration of intensive care unit stay. Underweight was the strongest predictor of adverse outcomes. Children meeting criteria for all 3 (stunting, wasting, and underweight) had 17.2 times higher odds of mortality ( P <0.001) than nonmalnourished children. Conclusions: Malnutrition was associated with mortality, infection, and longer intensive care unit stay in a global cohort of children undergoing VSD closure.

12 August 2025 in Methodist DeBakey Cardiovascular Journal
Verified
Journal Article
Open access
PDF file
JHJack A. Hoover
Jack A. Hoover
KCKeshika Catakam
Keshika Catakam
RWRachel Wittenberg
Rachel Wittenberg
JBJordan P. Bloom
Jordan P. Bloom
DYDoreen DeFaria Yeh
Doreen DeFaria Yeh
ASAda C. Stefanescu Schmidt
Ada C. Stefanescu Schmidt
Coronary artery anomalies are rare congenital abnormalities involving abnormal coronary artery origin and incomplete/abnormal vessel development. These anomalies encompass a broad anatomical spectrum with varied clinical presentations ranging from sudden cardiac arrest in young athletes to incidental findings in asymptomatic adults. While more data on anatomy and clinical presentation has emerged in the last decade, management remains highly individualized, guided by clinical presentation, anatomical characteristics, and patient preferences. This review provides an overview of each anomaly and recent advances in imaging, surgical planning, and risk stratification. We also highlight the challenges in optimizing management strategies, addressing gaps in evidence, and achieving consensus to refine risk stratification tools and support clinical decision-making.